As next-generation sequencing and other technologies have advanced, cancer care has improved dramatically. More sophisticated diagnostics, targeted treatments, immunotherapies and other approaches are making a big difference for patients. Unfortunately, there are still many blind spots. Kevin Keegan, GM of Oncology, Illumina chats with two prostate cancer survivors who are spearheading efforts to improve care. Rob Newson is a 30-year Navy SEAL veteran and swarm cancer catalyst. Brian McCloskey is an information technology marketing executive who founded the Prostate Cancer Lab. Subscribe to the Illumina video channel youtube.com/subscription_center?add_user=IlluminaInc A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Illumina technology is responsible for generating more than 90% of the world’s sequencing data.* Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond. *Data calculations on file. Illumina, Inc., 2015. View customer spotlight videos youtube.com/playlist?list=PLKRu7cmBQlajfheLzgbI4S7xBn7IDbt79 View Illumina webinars youtube.com/playlist?list=PLKRu7cmBQlahpXlnrrXlQw9itVJ8yHwUZ View Illumina product videos youtube.com/playlist?list=PLKRu7cmBQlaj6YuZmkfxZcT9twqDgP2Xd View Illumina support videos youtube.com/playlist?list=PLKRu7cmBQlajbm2KGsICWb-JOnusJfYvM Facebook: facebook.com/illuminainc LinkedIn: linkedin.com/company/illu... Instagram: instagram.com/illuminainc Twitter: twitter.com/illumina #HumanHealth #Genomics #GenomeEra #Illumina #Veterans #ProstateCancer #Swarm #PrecisionMedicine #IGF #IlluminaGenomicsForum #LightboxConversations